Noah Goodman Sells 5,000 Shares of Kymera Therapeutics (NASDAQ:KYMR) Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) insider Noah Goodman sold 5,000 shares of Kymera Therapeutics stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $114.00, for a total transaction of $570,000.00. Following the completion of the transaction, the insider owned 50,195 shares in the company, valued at approximately $5,722,230. This trade represents a 9.06% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Noah Goodman also recently made the following trade(s):

• On Monday, June 22nd, Noah Goodman sold 2,500 shares of Kymera Therapeutics stock. The stock was sold at an average price of $99.00, for a total transaction of $247,500.00.
• On Tuesday, April 14th, Noah Goodman sold 1,347 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.00, for a total transaction of $121,230.00.
• On Friday, April 10th, Noah Goodman sold 2,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $87.35, for a total transaction of $174,700.00.
• On Thursday, April 9th, Noah Goodman sold 8,264 shares of Kymera Therapeutics stock. The shares were sold at an average price of $87.50, for a total transaction of $723,100.00.

Kymera Therapeutics Stock Down 7.2%

Shares of Kymera Therapeutics stock opened at $108.12 on Friday. Kymera Therapeutics, Inc. has a 52-week low of $36.65 and a 52-week high of $130.05. The company’s 50-day simple moving average is $84.81 and its 200-day simple moving average is $82.31. The firm has a market cap of $8.89 billion, a price-to-earnings ratio of -30.29 and a beta of 2.02.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same quarter last year, the firm earned ($0.82) earnings per share. The firm’s revenue was up 55.5% compared to the same quarter last year. Equities research analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 EPS for the current year.

Institutional Investors Weigh In On Kymera Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. US Bancorp DE raised its holdings in Kymera Therapeutics by 9.8% during the third quarter. US Bancorp DE now owns 1,865 shares of the company’s stock worth $106,000 after purchasing an additional 166 shares during the last quarter. Glenmede Trust Co. NA grew its holdings in Kymera Therapeutics by 3.6% in the first quarter. Glenmede Trust Co. NA now owns 6,779 shares of the company’s stock valued at $565,000 after purchasing an additional 235 shares during the last quarter. Cetera Investment Advisers grew its holdings in Kymera Therapeutics by 7.5% in the first quarter. Cetera Investment Advisers now owns 3,602 shares of the company’s stock valued at $300,000 after purchasing an additional 252 shares during the last quarter. Larson Financial Group LLC increased its position in shares of Kymera Therapeutics by 36.9% in the fourth quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock valued at $83,000 after buying an additional 287 shares in the last quarter. Finally, Swiss National Bank increased its position in shares of Kymera Therapeutics by 0.3% in the first quarter. Swiss National Bank now owns 94,500 shares of the company’s stock valued at $7,871,000 after buying an additional 300 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the company. BTIG Research restated a “buy” rating and issued a $134.00 price target on shares of Kymera Therapeutics in a research note on Thursday. Loop Capital set a $97.00 price objective on Kymera Therapeutics in a research report on Monday, June 8th. Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a report on Monday, June 8th. UBS Group boosted their target price on shares of Kymera Therapeutics from $90.00 to $128.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Kymera Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $118.18.

Kymera Therapeutics News Roundup

Here are the key news stories impacting Kymera Therapeutics this week:

• Positive Sentiment: Kymera completed enrollment in its Phase 2b BROADEN2 trial for KT-621 ahead of schedule, accelerating the timeline for topline data to year-end 2026 and lifting optimism about the atopic dermatitis program. Article: Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026
• Positive Sentiment: BTIG Research reaffirmed a buy rating on Kymera Therapeutics and set a $134 price target, reinforcing bullish expectations for the stock. Article: Kymera Therapeutics Stock Climbs On Accelerated Timeline For Lead Atopic Dermatitis Program
• Neutral Sentiment: Kymera appointed Felix J. Baker, Ph.D. as chairman of the board, a leadership change that supports oversight but is less likely to move shares on its own. Article: Kymera Therapeutics Appoints Felix J. Baker, Ph.D. as Chairman of the Board of Directors
• Negative Sentiment: Recent insider selling, including shares sold by Noah Goodman and multiple sales by director Bruce Booth, may raise some caution despite being tied to a pre-arranged trading plan. Article: Insider transaction filing

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.